Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma Pimasertib Versus Dacarbazine in Patients With UnresectableNRAS-Mutated Cutaneous Melanoma: Phase II, Randomized,Controlled Trial with Crossover Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma- Phase II, Randomized, Controlled Trial with Crossover RETOUR MarcGuevreguian2021-03-22T20:41:42+01:00
